Literature DB >> 14716023

Mechanisms of Abeta clearance and catabolism.

Suzanne Y Guénette1.   

Abstract

Mutations that result in an increased generation of amyloid beta peptide (Abeta) account for less than 5% of Alzheimer's disease (AD). Data suggesting that late onset AD risk factors play a role in Abeta turnover in the brain have shifted some of the research focus to the study of Abeta clearance and degradation and the impact of these processes on the etiology of Alzheimer's disease (AD). This review will examine the data obtained from studies performed in knockout and transgenic mice on the proteases; the cells and the physiological mechanisms that play a part in the removal of Abeta from the brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14716023     DOI: 10.1385/NMM:4:3:147

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  97 in total

1.  Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases.

Authors:  K Shirotani; S Tsubuki; N Iwata; Y Takaki; W Harigaya; K Maruyama; S Kiryu-Seo; H Kiyama; H Iwata; T Tomita; T Iwatsubo; T C Saido
Journal:  J Biol Chem       Date:  2001-03-06       Impact factor: 5.157

2.  Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.

Authors:  Yasuji Matsuoka; Mitsuo Saito; John LaFrancois; Mariko Saito; Kate Gaynor; Vicki Olm; Lili Wang; Evelyn Casey; Yifan Lu; Chiharu Shiratori; Cynthia Lemere; Karen Duff
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

3.  Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

Authors:  Ronald B DeMattos; Kelly R Bales; David J Cummins; Steven M Paul; David M Holtzman
Journal:  Science       Date:  2002-03-22       Impact factor: 47.728

4.  Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques.

Authors:  H G Bernstein; S Ansorge; P Riederer; M Reiser; L Frölich; B Bogerts
Journal:  Neurosci Lett       Date:  1999-03-26       Impact factor: 3.046

5.  Degradation of intraendosomal insulin by insulin-degrading enzyme without acidification.

Authors:  F G Hamel; M J Mahoney; W C Duckworth
Journal:  Diabetes       Date:  1991-04       Impact factor: 9.461

6.  Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy.

Authors:  Mélanie Carpentier; Yves Robitaille; Luc DesGroseillers; Guy Boileau; Mieczyslaw Marcinkiewicz
Journal:  J Neuropathol Exp Neurol       Date:  2002-10       Impact factor: 3.685

7.  Degradation of amylin by insulin-degrading enzyme.

Authors:  R G Bennett; W C Duckworth; F G Hamel
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

8.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

9.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

10.  Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.

Authors:  S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

View more
  15 in total

Review 1.  Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease.

Authors:  Ralph A Nixon
Journal:  FASEB J       Date:  2017-07       Impact factor: 5.191

Review 2.  Clusterin in Alzheimer's disease: a player in the biological behavior of amyloid-beta.

Authors:  Xiang Li; Yifei Ma; Xu Wei; Yanpeng Li; Huijuan Wu; Jianhua Zhuang; Zhongxin Zhao
Journal:  Neurosci Bull       Date:  2013-12-19       Impact factor: 5.203

3.  Expression of familial Alzheimer disease presenilin 1 gene attenuates vesicle traffic and reduces peptide secretion in cultured astrocytes devoid of pathologic tissue environment.

Authors:  Matjaž Stenovec; Saša Trkov; Eva Lasič; Slavica Terzieva; Marko Kreft; José Julio Rodríguez Arellano; Vladimir Parpura; Alexei Verkhratsky; Robert Zorec
Journal:  Glia       Date:  2015-10-14       Impact factor: 7.452

4.  Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase.

Authors:  Jin Chu; Domenico Praticò
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

5.  Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet.

Authors:  Jia-Min Zhuo; Domenico Praticò
Journal:  Exp Gerontol       Date:  2009-12-11       Impact factor: 4.032

6.  The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.

Authors:  Yasuo Ihara; Maho Morishima-Kawashima; Ralph Nixon
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

7.  Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease.

Authors:  J-M Zhuo; G S Portugal; W D Kruger; H Wang; T J Gould; D Pratico
Journal:  Curr Alzheimer Res       Date:  2010-03       Impact factor: 3.498

8.  Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles.

Authors:  Jian-Guo Li; Jin Chu; Carlos Barrero; Salim Merali; Domenico Praticò
Journal:  Ann Neurol       Date:  2014-05-28       Impact factor: 10.422

9.  Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice.

Authors:  Iván Carrera; Ignacio Etcheverría; Lucía Fernández-Novoa; Valter Lombardi; Ramón Cacabelos; Carmen Vigo
Journal:  Int J Alzheimers Dis       Date:  2012-09-16

10.  Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model.

Authors:  Jin Chu; Domenico Praticò
Journal:  J Neuroinflammation       Date:  2012-06-14       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.